NCT03740217View on ClinicalTrials.gov

Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

February 6, 2019

Study Completion Date

February 6, 2019

Conditions
Phase 1
Interventions
DRUG

GKT137831

oral bioavailable small molecule that selectively inhibit NOX1 and NOX4

Trial Locations (1)

38610

Eurofins Optimed, Gières

Sponsors
All Listed Sponsors
collaborator

Eurofins Optimed

INDUSTRY

collaborator

York Bioanalytical Solution

INDUSTRY

lead

Calliditas Therapeutics AB

INDUSTRY